A Postmarketing Pharmacovigilance Study of Fenfluramine: Adverse Event Data Mining and Analysis Based on the US Food and Drug Administration Public Data Open Project (openFDA)

被引:0
|
作者
Chen, Tianyu [1 ]
Chen, Qiying [2 ]
Zhang, Yuezhen [1 ]
Liu, Ting [1 ,2 ]
机构
[1] Quanzhou Med Coll, 950 Donghai St, Quanzhou 362000, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 2, 950 Donghai St, Quanzhou 362000, Fujian, Peoples R China
关键词
Fenfluramine; openFDA; Adverse events; Pharmacovigilance; DRAVET;
D O I
10.1016/j.pediatrneurol.2025.03.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: A postmarketing analysis of the adverse events (AEs) associated with fenfluramine (FFA) was conducted using the US Food and Drug Administration's Open Public Data Program (openFDA). Methods: The openFDA database was queried to retrieve FFA AE reports. Two algorithms, namely, the reporting odds ratio (ROR) and proportional reporting ratio, were employed for the purpose of detecting potential safety signals. Results: From the openFDA data platform, a total of 6,269,521 AE reports were collected during the study period; the number of AE reports with FFA as the primary suspect was 2386. Of these, 1526 (63.96%) were reported by consumers or non-health professionals, 2009 (84.20%) were reported by the United States, 1053 (44.13%) were unknown indications, and serious AEs were reported in 1315 cases (55.11%). A total of 62 signals were generated. The top 10 signals included atonic seizures (ROR of 918.52, 95% confidence interval [CI]: 670.65-1257.99), seizure clusters (ROR of 787.02, 95% CI: 595.26-1040.56), mitral valve thickening (ROR of 773.94, 95% CI: 463.47-1292.38), pulmonary valve incompetence (ROR of 600.71, 95% CI: 432.09-835.13), echocardiogram abnormal (ROR of 417.13, 95% CI: 307.87-565.16), change in seizure presentation (ROR of 287.55, 95% CI: 214.81-384.91), tricuspid valve incompetence (ROR of 221.42, 95% CI: 179.68-272.84), aortic valve incompetence (ROR of 176.59, 95% CI: 131.89-236.45), tonic convulsion (ROR of 173.68, 95% CI: 110.28-273.54), and myoclonic epilepsy (ROR of 158.05, 95% CI: 102.60-243.46). Conclusions: This study employed the openFDA database to identify safety signals associated with FFA, thereby offering significant insights for clinical monitoring and risk identification in patients undergoing FFA therapy. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [21] RHEUMATIC AND MUSCULOSKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: DATA MINING OF THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM
    Pundole, X.
    Sarangdhar, M.
    Suarez-Almazor, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 147 - 148
  • [22] Adverse drug events of denosumab: Data-mining based on the United States Food and Drug Administration Adverse Event Reporting System database
    Liu, Shaohua
    Jiang, Wangyan
    Guo, Jieru
    Zhou, Xinrong
    Liu, Zhelong
    JOURNAL OF RESEARCH IN PHARMACY, 2024, 28 (04): : 1220 - 1230
  • [23] Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System
    Jae Min
    Vicki Osborne
    Allison Kowalski
    Mattia Prosperi
    Drug Safety, 2018, 41 : 313 - 320
  • [24] Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System
    Min, Jae
    Osborne, Vicki
    Kowalski, Allison
    Prosperi, Mattia
    DRUG SAFETY, 2018, 41 (03) : 313 - 320
  • [25] A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis
    Hatano, Masakazu
    Araki, Haruna
    Saito, Takeo
    Yamada, Shigeki
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2024, 22 (03) : 442 - 450
  • [26] Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
    Fang, Runan
    Zhou, Yang
    Han, Lu
    Chen, Wenjing
    Guan, Ning
    Li, Jianhong
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Kvist, Annika Vestergaard
    Faruque, Junaid
    Vallejo-Yague, Enriqueta
    Weiler, Stefan
    Winter, Elizabeth M.
    Burden, Andrea M.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [28] Cardiovascular safety profile of romosozumab: A pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system (FAERS)
    Kvist, Annika
    Faruque, Junaid A. Y.
    Burden, Andrea M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 159 - 160
  • [29] A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
    Tian, Yalan
    Jin, Min
    Ning, Hong
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [30] Adverse Drug Reaction Mining in Pharmacovigilance Data Using Formal Concept Analysis
    Villerd, Jean
    Toussaint, Yannick
    Louet, Agnes Lillo-Le
    MACHINE LEARNING AND KNOWLEDGE DISCOVERY IN DATABASES, PT III, 2010, 6323 : 386 - 401